Tags

Type your tag names separated by a space and hit enter

[Influence of retinoids on the bioavailability of methoxy-8-psoralen].
Ann Dermatol Venereol. 1991; 118(4):273-5.AD

Abstract

The retinoid-PUVA combination has been recognized as a satisfactory treatment of psoriasis. The absorption of 8-methoxypsoralen (8-MOP) is subject to wide interindividual variations under the influence of factors that are not yet known with certainty but are independent of age, sex and food taken at the same time as the psoralen. Whether concomitant retinoid administration influences the bioavailability of 8-MOP was considered an interesting question. The pharmacokinetics of 8-MOP were studied and compared in two populations of psoriatic patients: 119 patients treated with PUVA alone (psoralen-ultraviolet A) and 40 patients treated with the etretinate-PUVA combination (RePUVA). 8-MOP was assayed by the modified Ljunggren method 1 h, 1 h 30, 2 h, 2 h 30, 3 h and 4 h after ingestion of 8-MOP. The pharmacokinetic values recorded were: time and peak value of maximum plasma 8-MOP concentration (Tmax, Cmax) and area under the curve of time-related 8-MOP concentrations (AUC). The results obtained were as follows: Tmax PUVA 2 h 02 +/- 53 min RePUVA 1 h 56 +/- 50 min Cmax PUVA 159.12 +/- 88.85 ng/ml RePUVA 163.63 +/- 92.85 ng/ml AUC PUVA 343.33 +/- 211.06 ng*h/ml RePUVA 388.12 +/- 251.03 ng*h/ml Statistical analysis showed no significant difference in pharmacokinetic values between patients on PUVA alone and patients on RePUVA. Taking etretinate therefore does not alter the pharmacokinetics of 8-MOP and should not require any change in PUVA treatment.

Authors+Show Affiliations

Beani JC
Clinique Dermatologique, CHRU Grenoble.
Bonnot D
No affiliation info available
Berthod F
No affiliation info available
Boitard M
No affiliation info available
Reymond JL
No affiliation info available
Beriel H
No affiliation info available
Amblard P
No affiliation info available

MeSH

AdolescentAdultAgedAged, 80 and overBiological AvailabilityDrug InteractionsEtretinateFemaleHumansMaleMethoxsalenMiddle AgedPUVA TherapyPsoriasis

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

fre

PubMed ID

2069337

Citation

Beani, J C., et al. "[Influence of Retinoids On the Bioavailability of Methoxy-8-psoralen]." Annales De Dermatologie Et De Venereologie, vol. 118, no. 4, 1991, pp. 273-5.
Beani JC, Bonnot D, Berthod F, et al. [Influence of retinoids on the bioavailability of methoxy-8-psoralen]. Ann Dermatol Venereol. 1991;118(4):273-5.
Beani, J. C., Bonnot, D., Berthod, F., Boitard, M., Reymond, J. L., Beriel, H., & Amblard, P. (1991). [Influence of retinoids on the bioavailability of methoxy-8-psoralen]. Annales De Dermatologie Et De Venereologie, 118(4), 273-5.
Beani JC, et al. [Influence of Retinoids On the Bioavailability of Methoxy-8-psoralen]. Ann Dermatol Venereol. 1991;118(4):273-5. PubMed PMID: 2069337.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Influence of retinoids on the bioavailability of methoxy-8-psoralen]. AU - Beani,J C, AU - Bonnot,D, AU - Berthod,F, AU - Boitard,M, AU - Reymond,J L, AU - Beriel,H, AU - Amblard,P, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 273 EP - 5 JF - Annales de dermatologie et de venereologie JO - Ann Dermatol Venereol VL - 118 IS - 4 N2 - The retinoid-PUVA combination has been recognized as a satisfactory treatment of psoriasis. The absorption of 8-methoxypsoralen (8-MOP) is subject to wide interindividual variations under the influence of factors that are not yet known with certainty but are independent of age, sex and food taken at the same time as the psoralen. Whether concomitant retinoid administration influences the bioavailability of 8-MOP was considered an interesting question. The pharmacokinetics of 8-MOP were studied and compared in two populations of psoriatic patients: 119 patients treated with PUVA alone (psoralen-ultraviolet A) and 40 patients treated with the etretinate-PUVA combination (RePUVA). 8-MOP was assayed by the modified Ljunggren method 1 h, 1 h 30, 2 h, 2 h 30, 3 h and 4 h after ingestion of 8-MOP. The pharmacokinetic values recorded were: time and peak value of maximum plasma 8-MOP concentration (Tmax, Cmax) and area under the curve of time-related 8-MOP concentrations (AUC). The results obtained were as follows: Tmax PUVA 2 h 02 +/- 53 min RePUVA 1 h 56 +/- 50 min Cmax PUVA 159.12 +/- 88.85 ng/ml RePUVA 163.63 +/- 92.85 ng/ml AUC PUVA 343.33 +/- 211.06 ng*h/ml RePUVA 388.12 +/- 251.03 ng*h/ml Statistical analysis showed no significant difference in pharmacokinetic values between patients on PUVA alone and patients on RePUVA. Taking etretinate therefore does not alter the pharmacokinetics of 8-MOP and should not require any change in PUVA treatment. SN - 0151-9638 UR - https://www.unboundmedicine.com/medline/citation/2069337/[Influence_of_retinoids_on_the_bioavailability_of_methoxy_8_psoralen]_ DB - PRIME DP - Unbound Medicine ER -